Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
NCT ID: NCT04421846
Last Updated: 2025-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
400 participants
INTERVENTIONAL
2020-11-25
2027-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiology of Suspected Epileptic Seizures
NCT04147663
Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy
NCT05422664
Evaluating the Role of Inflammation in Neonatal Epileptogenesis
NCT04259125
Prevalence and Pattern of Headache in Pediatric Epilepsy
NCT06868251
Assessment of Adults Epidemiological Characteristics of Status Epilepticus in the French West Indies and in French Guiana
NCT05246566
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The severity of these epilepsies requires significant efforts to (i) identify new therapeutic strategies able to control the evolution of dysimmune encephalitis and refractory status epilepticus, (ii) to identify their etiologies and (iii) to propose neuroprotective strategies.
Therefore, the investigators will organize a collection of biological samples (blood, cerebrospinal fluid, post-mortem brain tissues) and paraclinical data (electroencephalogram, evoked potential, CT, MRI) in patients with severe epilepsies, whether or not associated with autoantibodies, and/or evolving into status epilepticus.
This study should bring new insights allowing to better understand mechanisms that trigger the emergence of an epileptic brain (epileptogenesis) through :
(i) the identification and characterization of new pathophysiological pathways involving autoimmunity directed against the cerebral cortex and associated with severe epilepsy (ii) the identification and characterization of pathophysiological pathways participating in the excitotoxicity observed in status epilepticus.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 : Status epilepticus
Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)
Collection of biological samples and clinical/paraclinical data
Group 2 : Dysimmune encephalitis
Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Collection of biological samples and clinical/paraclinical data
Group 3 : Control patients
Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Collection of biological samples and clinical/paraclinical data
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Collection of biological samples and clinical/paraclinical data
Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)
Collection of biological samples and clinical/paraclinical data
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 2 years or above, with status epilepticus.
* Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
* Patients or relatives have been informed and given free informed and written consent to participate
* Patients under legal protection (guardianship, curatorship) or not
Group 2:
* Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.
* Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
* Patients or relatives have been informed and given free informed and written consent to participate
* Patients under legal protection (guardianship, curatorship) or not
Group 3:
* Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis.
* Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
* Patients or relatives have been informed and given free informed and written consent to participate
* Patients under legal protection (guardianship, curatorship) or not
Exclusion Criteria
* Women with known or clinically detected pregnancy.
* Patient deprived of liberty
* Patients with known neurodegenerative disease.
Group 2:
* Women with known or clinically detected pregnancy.
* Patient deprived of liberty
* Patients have been already treated by corticoids or IgIV.
Group 3:
* Women with known or clinically detected pregnancy.
* Patient deprived of liberty.
* Patients with status epilepticus.
* Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke.
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vincent NAVARRO, Pr
Role: PRINCIPAL_INVESTIGATOR
Hôpital Pitié Salpêtrière - Assitance Publique Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital de la Pitié Salpêtrière
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A00053-36
Identifier Type: OTHER
Identifier Source: secondary_id
APHP200306
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.